Cipla Ltd is quoting at Rs 1286.4, down 1.05% on the day as on 13:19 IST on the NSE. The stock tumbled 14.73% in last one year as compared to a 3.15% rally in NIFTY and a 7.68% spurt in the Nifty ...

With India’s semaglutide patent expiring on 20 March, about 50 branded generics are expected to enter the market.

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announces that it has entered into an agreement with Cipla Limited and Cipla USA, Inc. to settle the ...

Semaglutide prices in India are set to drop sharply as generics enter the market after patent expiry, improving affordability for diabetes and weight-loss treatments.

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announces that it has entered into an agreement ...

Top 30 pharma companies post 12% revenue growth in first nine months, net profit up only by 2.8%: Sanjay Pingle, Mumbai Friday, March 13, 2026, 08:00 Hrs [IST] The aggregate finan ...

Semaglutide works by imitating the natural hormone glucagon-like peptide-1 (GLP-1), which plays a key role in managing blood sugar.

Market expert Raja Venkatraman shares his top stock picks for 18 March. Here’s his technical outlook and trade strategy.

The generic versions of semaglutide are expected to be at least 50% cheaper— ₹5,000 for a weekly dose—than Ozempic in India .

Pharmaceutical companies in India are driving innovation, biosimilars, APIs & global exports while strengthening research, manufacturing & healthcare access.

With semaglutide patent ending, Indian pharma firms are set to launch lower-cost versions, prompting hospitals and clinics to expand obesity services ahead of a surge in demand.